Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220551 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants
A Phase 1 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT07220551 is a Phase 1 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 14 participants.
The verdict
NCT07220551, a Phase 1 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the relative bioavailability of UCB0022 Formulation 2 (Test) versus Formulation 1 (Reference) in healthy participants following single oral administration.
Interventions
- DRUG UCB0022
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2025-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220551
The ClinicalTrials.gov registry entry for NCT07220551 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which UCB0022 is the first listed.
NCT07220551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07220551 about?
NCT07220551 is a clinical study titled "A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants". The purpose of this study is to estimate the relative bioavailability of UCB0022 Formulation 2 (Test) versus Formulation 1 (Reference) in healthy participants following single oral administration.
What is the current status of trial NCT07220551?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2025-10-23. Estimated completion is 2025-12-16.
What interventions are being tested in trial NCT07220551?
The interventions under investigation include: UCB0022 (DRUG).
Who is sponsoring clinical trial NCT07220551?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.